Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of subretinal ABBV-RGX-314 in neovascular age-related macular degeneration
2023-505750-17-00Phase 2Authorised
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Gene Therapies
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of surabgene lomparvovec in exudative macular degeneration, sponsored by AbbVie Inc. Primary endpoint: Incidence of ocular adverse events and serious adverse events. Planned start Jul 2025; status: authorised.
02
Drugs
surabgene lomparvovec
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2023-505750-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505750-17-00.